ClinicalTrials.gg
CompletedNCT04605302Updated May 27, 2026Results posted

Comparative Study of MCCE With/Without Tether vs Conventional Upper Endoscopy in Patients With Upper Abdominal Symptoms

An interventional study of MCC/MCC-T and Standard gastroscopy in Upper Gastrointestinal Symptoms, sponsored by AnX Robotica Corp.. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-27.

Sponsored by AnX Robotica Corp. · Not applicable, Interventional, and Diagnostic

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
27
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

A prospective single blinded, tandem study, comparing a magnetically controlled capsule with or without a tether (MCC or MCC-T) with conventional upper endoscopy for the diagnosis of patients with upper abdominal symptoms.

Read the detailed description

In the US patients commonly undergo esophagogastroduodenoscopy (EGD) for upper abdominal symptoms to try to resolve whether they have gastroesophageal reflux disease or functional dyspepsia, if they are older than the age of 60 with symptoms, or have alarm symptoms such as unexplained weight loss, persistent nausea and vomiting or if they have symptoms that are refractory to acid suppression therapy. Given the increasing burden of digestive disease in the US, the use of EGD is increasing in volume nationwide. EGD usually requires either conscious sedation or monitored anesthesia sedation, which has put an additional cost burden on the healthcare system. Since MCC or MCC-T does not require sedation, it offers an attractive option for both patients and clinicians alike.

The aim of this study is to compare in the same patient the accuracy of the MCC and MCC-T and EGD in patients presenting with upper abdominal symptoms.

02

Conditions studied

  • Upper Gastrointestinal Symptoms
03

In context

Lead sponsor

AnX Robotica Corp. is the lead sponsor of 3 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient is able to provide
  2. Patient has appropriate indications for EGD including symptoms of, but not limited to upper abdominal pain, acid reflux, heartburn, iron deficiency anemia, weight loss, bloating, belching, nausea, vomiting and atypical chest pain.

Exclusion criteria

Exclusion Criteria:

  1. Patient with dysphagia.
  2. Patient with previous intestinal surgery.
  3. Patient with Crohn's disease or other potential obstructive conditions, unless there is a recent CTE, MRE or patency capsule performed to exclude an obstructive lesion that may retain the capsule.
  4. Female patient who is pregnant.
  5. Patient with implanted medical device that would be potentially affected by magnets or radiofrequency emissions (e.g., pacemakers, implanted cardiac defibrillators).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    Single Arm Tandem Study

    Patients are assigned to swallow a magnetically controlled capsule first then undergo standard gastroscopy

    Device: MCC/MCC-T · Device: Standard gastroscopy

Interventions

  • DeviceMCC/MCC-T

    Magnetically controlled capsule endoscopy (MCC), with or without tether, is used to visualize the upper gastrointestinal tract

    Also known as: Magnetic controlled capsule endoscopy with/without tether

  • DeviceStandard gastroscopy

    Diagnostic endoscopic procedure that visualizes the upper part of the gastrointestinal tract down to the duodenum

    Also known as: EGD

06

What researchers measure

Primary outcomes

  1. Compare Total Number of Lesions Identified Via MCCE Versus EGD

    A count of the cumulative total number of lesions identified by the MCCE procedure versus a count of the cumulative total number of lesions identified by the EGD procedure.

    Time frame: Day of EGD procedure

  2. Number of Adverse Events

    Occurrence and severity of adverse event related to MCCE procedure versus EGD procedure. Outcomes noted in AE/SAE sections. Adverse Events were NOT collected in the Healthy Volunteer arm.

    Time frame: 24-72 hour follow up phone call post EGD procedure

Secondary outcomes

  1. Participant Satisfaction Score With MCCE Procedure Versus EGD Procedure

    Participant acceptance of MCCE versus EGD (units on a scale, scale of 1 to 10; when 1 is the lowest and 10 is the highest score)

    Time frame: 24-72 hour follow up phone call post EGD procedure

  2. To Compare Rate of Complete Examination for the MCC and EGD Procedures

    Total count of participants who were able to complete their MCC procedure, compared to a total count of participants able to complete their EGD procedure.

    Time frame: Day of procedure

07

Results

Posted May 27, 2026

Participant flow

11 healthy volunteers had the MCCE procedure for training purposes only, they did not have the EGD procedure; demographic data was collected, however outcome data was not collected or analyzed

Participant flow — Overall Study
MilestoneSingle Arm Tandem ProceduresHealthy Volunteers
Started1611
Completed1611
Not completed00

Outcome measures

PrimaryCompare Total Number of Lesions Identified Via MCCE Versus EGD

A count of the cumulative total number of lesions identified by the MCCE procedure versus a count of the cumulative total number of lesions identified by the EGD procedure.

Time frame:
Day of EGD procedure
Reported as:
Number · # of lesions identified
Compare Total Number of Lesions Identified Via MCCE Versus EGD
# of lesions identifiedMCC ProcedureEGD Procedure
Compare Total Number of Lesions Identified Via MCCE Versus EGD1012
PrimaryNumber of Adverse Events

Occurrence and severity of adverse event related to MCCE procedure versus EGD procedure. Outcomes noted in AE/SAE sections. Adverse Events were NOT collected in the Healthy Volunteer arm.

Time frame:
24-72 hour follow up phone call post EGD procedure
Reported as:
Number · events
Number of Adverse Events
eventsSingle Arm Tandem Procedures
# of AEs identified with MCC1
# of AEs identified with EGD2
SecondaryParticipant Satisfaction Score With MCCE Procedure Versus EGD Procedure

Participant acceptance of MCCE versus EGD (units on a scale, scale of 1 to 10; when 1 is the lowest and 10 is the highest score)

Time frame:
24-72 hour follow up phone call post EGD procedure
Reported as:
Mean · units on a scale
Participant Satisfaction Score With MCCE Procedure Versus EGD Procedure
units on a scaleSingle Arm Tandem Study
Satisfaction with MCCE procedure8.13 ± 2.33
Satisfaction with EGD procedure7.56 ± 2.66
SecondaryTo Compare Rate of Complete Examination for the MCC and EGD Procedures

Total count of participants who were able to complete their MCC procedure, compared to a total count of participants able to complete their EGD procedure.

Time frame:
Day of procedure
Reported as:
Number · participants
To Compare Rate of Complete Examination for the MCC and EGD Procedures
participantsMCC ProcedureEGD Procedure
To Compare Rate of Complete Examination for the MCC and EGD Procedures1616

Adverse events

Collected over Participants were followed in this study for 24-72 hours post the EGD procedure. Any open AEs to be followed by the prescribing physician.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Single Arm Tandem Procedures0/16 (0%)0/16 (0%)3/16 (18.8%)
Most frequent other events
Most frequent other events
EventSingle Arm Tandem Procedures
abdominal cramping with MCCE procedureGastrointestinal disorders1/3
vomiting with EGD procedureGastrointestinal disorders1/16
acid reflux with EGD procedureGastrointestinal disorders1/16

Baseline characteristics

Participants had MCCE procedure followed by an EGD procedure

Age, Continuous
Age, Continuous(years)Single Arm Tandem ProceduresHealthy VolunteersTotal
Median49.25 ± 13.7752.45 ± 7.9050.56 ± 11.66
Sex: Female, Male
Sex: Female, Male(Participants)Single Arm Tandem ProceduresHealthy VolunteersTotal
Female9716
Male7411
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Single Arm Tandem ProceduresHealthy VolunteersTotal
Hispanic or Latino202
Not Hispanic or Latino111122
Unknown or Not Reported303
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Single Arm Tandem ProceduresHealthy VolunteersTotal
American Indian or Alaska Native000
Asian022
Native Hawaiian or Other Pacific Islander000
Black or African American101
White15924
More than one race000
Unknown or Not Reported000
Population
Population(Participants)Single Arm Tandem ProceduresHealthy VolunteersTotal
Count of participants161127
08

Study locations

1 site
  • University of Massachusetts Medical School
    Worcester, Massachusetts 01655, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2021 to primary completion in Jun 2021, 4 months.

Results were first posted in May 2026, 4 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 8, 2020
First posted
Oct 28, 2020
StartActual
Feb 10, 2021
Primary completionActual
Jun 30, 2021
CompletionActual
Mar 30, 2023
Results first posted
May 27, 2026
Last update
May 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04605302
Lead sponsor
AnX Robotica Corp.
Responsible party
Sponsor
First posted
Oct 28, 2020
Start date
Feb 10, 2021
Primary completion
Jun 30, 2021
Completion
Mar 30, 2023
Results posted
May 27, 2026
Last update
May 27, 2026

Study contacts

David R Cave, MD, PhD
principal investigator · University of Massachusetts, Worcester

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion